CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 363 enrolled
Drug / intervention
Prospekta +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04569357
NCT04569357Phase 3Completed
CompareCT.gov

Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children

Materia Medica Holding·interventional·Posted Sep 29, 2020·Updated Aug 1, 2024

In Brief

A Phase 3 clinical trial evaluating Prospekta and Placebo for Attention Deficit Hyperactivity Disorder. Completed, enrolled 363 participants across 31 sites.

Detailed Summary

Purpose of the study: • evaluate the efficacy and safety of Prospekta in the treatment of attention deficit/hyperactivity disorder in children.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder
CountriesRussia
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedSep 29, 2020
Enrollment StartNov 20, 2020
Primary CompletionFeb 18, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.8 years ago

Interventions

Prospektadrug

Oral administration.

Placebodrug

Oral administration.